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ABSTRACT* 
Nonadherence to medication treatment regimens is 
a major preventable risk behavior in both acute and 
chronic diseases. Community pharmacists are 
facilitators in community care for promoting 
medication adherence and they should implement 
interdisciplinary medication adherence programs. 
To do so, pharmacists should be educated in 
medication adherence, and new pharmaceutical 
care policies should be implemented. The 
healthcare system should evolve to better meet the 
specific needs of patients.  
Aims: this article describes what has been 
undertaken in the last decade in medication 
adherence in terms of education, research, practice 
and policy in Switzerland. 
Methods: Medline was searched, with the search 
limited to Switzerland. The three Swiss pharmacy 
schools were also contacted to collect information 
about the medication adherence content of both 
their courses and research programs. National 
policies related to medication adherence were also 
reviewed for relevant content. 
Results: Education: two pharmacy schools offer 
courses devoted specifically to medication 
adherence. The number of hours dedicated to the 
topic varies between 4 to13. Research: a total of 16 
studies met the inclusion criteria. Chronic patients 
were the focus of 9 studies. Medication adherence 
was the primary outcome of all studies; 10 studies 
also measured clinical outcomes. Nine studies 
evaluated the prevalence of medication 
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nonadherence; three studies evaluated the 
feasibility of new technologies for monitoring 
adherence; three studies evaluated medication 
adherence enhancing programs. Policies: three 
cognitive pharmaceutical services are reimbursed 
by healthcare insurers, which are directly related to 
medication adherence. 
Conclusions: Pharmacists in Switzerland have been 
actively involved in medication adherence research 
since the mid ’90s. Specific medication adherence 
courses have entered the curriculum of pharmacy 
schools, and policies in Switzerland are slowly 
beginning to meet needs of chronic patients by the 
introduction of pharmaceutical cognitive services 
and reimbursement fees.  
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CUMPLIMIENTO: REVISIÓN DE LA 
EDUCACIÓN, INVESTIGACIÓN, PRÁCTICA 
Y POLÍTICA EN SUIZA 
 
RESUMEN 
El incumplimiento de los tratamientos 
farmacológicos es un comportamiento de riesgo 
serio prevenible tanto en enfermedades agudas 
como crónicas. Los farmacéuticos comunitarios son 
son facilitadores en atención primaria para 
promover la adhesión a la medicación y deberían 
implantar programas interdisciplinarios de 
cumplimiento medicamentoso. Para ello, los 
farmacéuticos deben ser educados en adhesión a la 
medicación y deben implantarse nuevas políticas de 
atención farmacéutica. El sistema sanitario debería 
evolucionar para cumplir mejor las necesidades 
específicas de los pacientes. 
Objetivos: este artículo describe lo que se ha 
realizado en la última década sobre adhesión a 
medicación en términos de educación, 
investigación, práctica y política en Suiza.  
Métodos: Se buscó en Medline, limitando la 
búsqueda a Suiza. Se contactó a las tres facultades 
de Farmacia de Suiza para recoger información 
tanto sobre sus cursos como sobre sus programas de 
investigación. También se revisaron las políticas 
nacionales a la búsqueda de contenidos relevantes. 
Resultados: Educación: Dos facultades de farmacia 
ofrecieron cursos específicamente dedicados a 
adhesión a la medicación. El número de horas 
dedicado a estos temas varió de 4 a 13. 
Investigación: 16 estudios cumplieron los criterios 
de inclusión. Los pacientes crónicos fueron el foco 
de 9 estudios. El cumplimiento de la medicación 
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fue el resultado principal de todos los estudios; 10 
estudios también midieron resultados clínicos. 9 
estudios evaluaron la prevalencia del 
incumplimiento; 3 estudios evaluaron la viabilidad 
de las nuevas tecnologías para el seguimiento de la 
adhesión; 3 estudios evaluaron programas de 
aumento de cumplimiento. Políticas: · servicios 
cognitivos farmacéuticos están siendo remunerados 
por las aseguradoras y están directamente 
relacionados con el cumplimiento de la medicación. 
Conclusiones: La farmacia en Suiza se ha 
involucrado activamente en investigación sobre 
cumplimiento de la medicación desde mediados de 
los 90. Cursos específicos de cumplimiento de la 
medicación han entrado a formar parte del currículo 
de las facultades de farmacia, y las políticas en 
Suiza están comenzando lentamente a satisfacer las 
necesidades de los pacientes crónicos con la 
introducción de servicios cognitivos farmacéuticos 
y remuneración. 
 
Palabras clave: Adherencia a la medicación. 
Farmacéuticos. Suiza. 
 
 
 
 
INTRODUCTION 
Nonadherence to medication treatment regimens 
(‘medication nonadherence’) is a major preventable 
risk behavior in chronic diseases. Missing doses is 
a natural behavior – every patient misses doses 
once in a while usually without important clinical 
consequences - but it may become pernicious if it is 
frequent enough to impact negatively on therapeutic 
outcomes. This is exemplified in the treatment of the 
Human Immunodeficiency Virus (HIV). Since the 
mid ’90, HIV patients have become chronic patients 
largely due to the new potent combined 
antiretroviral therapies. However, ongoing 
medication adherence to the treatments needs to 
remain high (>90%) to prevent (1) the emergence of 
drug resistance strains and (2) treatment failure.1 
Medication adherence has become the new MeSH 
term in Medline since January 2009 and replaces 
the old term, patient compliance. Adherence is an 
active, intentional and responsible process of care 
in which the patient works to maintain health in 
close collaboration with healthcare providers. 
Medication adherence implies two different 
behaviors. On the one hand, persistence, which 
means the duration of dosing before patient’s 
premature interruption of treatment, and, on the 
other hand, good quality of execution, which 
describes the daily patterns of patient adherence 
behavior (e.g. percentage of days with correct 
dosing, percentage of correct dosing intervals, drug 
holidays). 
It has long been recognized that healthcare systems 
need to evolve to better meet the specific needs of 
chronic patients.2 Healthcare providers should 
support their chronic patients by prescribing and 
delivering pharmacologically-sound treatments 
adjusted to specific patient needs. To ensure 
optimal use of treatment, healthcare providers must 
also explore patient knowledge and understanding 
of disease and its treatment, beliefs and 
expectations, motivation, self-efficacy and readiness 
to treatment, and behavioral skills to ensure optimal 
integration of treatment into patient life style. 
Medication adherence is a dynamic behavior, which 
changes with time according to life circumstances. 
Therefore, it should be tracked over the long-term. 
Chronic patients encounter several healthcare 
providers along their way, among them, their 
general practitioner, specialist physicians and their 
pharmacist. Unfortunately, healthcare providers 
usually do not collaborate. In fact, care is often 
sequential and inefficient as potentially useful 
information is not consistently exchanged or 
reinforced by all care providers.  
A key professional responsibility of community 
pharmacists is to promote medication adherence. In 
fact, pharmacists are well positioned to identify and 
address medication adherence issues with their 
patients and provide an adherence report for 
physician review. This would allow physicians to 
consider adherence results as part of their decision 
making. Pharmacists are ideal partners and 
facilitators in community care for promoting 
medication adherence as it is often less difficult for 
patients to address nonadherence issues with 
someone other than the prescribing physician, to 
whom they may feel bonded.  
However, to fulfill this role, pharmacists as well as 
other healthcare providers must be educated in 
medication adherence. Specific courses should 
cover medication adherence theories, relevant 
communication skills and relevant practice 
guidelines. An example is the recently published 
British National Institute for Health and Clinical 
Excellence (NICE) medication adherence guidelines 
for professionals and patients.3 
Meanwhile, patient expectations of pharmacist’s 
role should also evolve. Patients need to be 
informed of the potential and progressive shift from 
pharmacists dispensing chronic medications to 
pharmaceutical care programs, which emphasize 
the resolution of drug related problems such as 
medication nonadherence. Medication 
nonadherence should be addressed specifically with 
patients very early on in the course of their chronic 
treatment before nonadherence has become such 
an issue that patients become reluctant to express 
concerns and perceived difficulties with prescribed 
treatments. 
This article describes what has been undertaken in 
Switzerland in terms of the education, research, 
practice and policy of medication adherence. 
 
METHODS  
Medication adherence education, research and 
practice 
The three Swiss pharmacy schools – Basel, 
Geneva, and Zurich - were contacted and were 
asked to fill in a structured self-completion 
questionnaire about medication adherence in their 
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curricula, their medication adherence related 
research and the practice of medication adherence 
specific services in community pharmacy. Two 
items of the questionnaire focused on pre-graduate 
and post-graduate education in medication 
adherence. Respondents were asked to provide 
detailed information about the way education in 
medication adherence is structured and when the 
courses are taught. One item requested information 
on past and on-going research into medication 
adherence and for any related references. Three 
items were devoted to practice in community 
pharmacy: (1) the way community pharmacists 
address medication adherence with their chronic 
patients, (2) whether community pharmacists run 
specific adherence intervention programs, and (3) 
whether any interdisciplinary collaboration exists 
between community pharmacists and other 
healthcare providers or the pharmaceutical industry 
for promoting medication adherence.  
Research in medication adherence 
The database MEDLINE was searched, with the 
search limited to Switzerland from 1975 to present. 
The following key-words were used: patient 
compliance OR patient adherence OR medication 
adherence OR pharmaceutical services OR 
pharmaceutical care. Searches were also 
conducted based on the names of key Swiss 
researchers in the areas of medication adherence 
and pharmaceutical services. The study was 
included if pharmacists were involved in measuring 
and/or supporting patients’ adherence to chronic 
medication. All study designs were included. Each 
retrieved article was then reviewed based on the 
study design, methods for measuring medication 
adherence, study outcomes and results.  
Policy 
National policies related to medication adherence 
were also reviewed. The policies are published in 
an agreement (Convention tarifaire RBPIII) between 
the Swiss Pharmacist Society and Swiss health 
insurers (‘santé suisse’). 
 
RESULTS AND DISCUSSION 
Medication adherence education 
All three Swiss pharmacy schools responded to the 
questionnaire. They all offer the Bachelor, a 3-year 
undergraduate degree, and a 2-year Master of 
Pharmacy degree. During the Bachelor degree, 
students receive an education in basic medical and 
pharmaceutical sciences. Depending on the 
Pharmacy Schools, 2 types of Masters degree are 
available: 1) a Masters degree in Pharmacy and a 
Masters degree in industrial pharmaceutical 
sciences. During the first year Masters degree in 
Pharmacy, students complete a 6-months advanced 
pharmaceutical sciences course and a 16-weeks 
research project. During the second year of the 
Masters degree in Pharmacy, students complete 20 
to 30 weeks internship in community pharmacies 
and 10 optional weeks in hospital pharmacies, and 
attend a 12-week on campus course. The Masters 
degree in Pharmacy is completed by the Federal 
examination for registered pharmacists. Registered 
pharmacists can then work in community 
pharmacies. Advanced Masters or diploma are also 
available, for example a Master of Advanced 
Studies in hospital pharmacy, a Master in 
Pharmaceutical Economics and Policy, a Master in 
Public Health or a diploma in community health.4 
The curriculum regarding medication adherence 
varies widely from one University to the other. 
Students of all pharmacy schools are taught the 
topic during the masters training program. Two 
pharmacy schools offer specific courses devoted to 
medication adherence and related topics such as 
patient empowerment, and communication skills 
and techniques. The number of dedicated hours 
during the Masters varies between 4 to 13 hours. 
The third school did not approach the issue 
specifically but teaches medication adherence when 
appropriate during other therapeutic courses. Table 
1 summarizes the medication adherence courses in 
the three Swiss pharmacy schools. 
In Swiss pharmacy schools, medication adherence 
is slowly becoming recognized as an important 
issue that needs to be taught specifically. 
Nevertheless, the topic probably deserves more 
attention as patient behavior towards prescribed 
medications is an important modifier of the 
effectiveness of community-based chronic 
treatment. Moreover, the topic is taught at the end 
of the curriculum, which then coincides with student 
training in community pharmacies. However, it is 
important to increase students’ awareness earlier 
on and to give them the opportunity to develop 
relevant skills more gradually.  
Ongoing education in medication adherence for 
registered pharmacists is regularly provided by 
Universities, and national or local organizations 
involved in pharmacists’ continuous education, for 
example, the Swiss Pharmacists Association, 
pharmaSuisse, and its program pharmActuel5 or the 
Association of community pharmacists CAP6 
(Centre d’animation des pharmaciens). 
Medication adherence education is also provided by 
other healthcare professionals, for example the 
University of Geneva offers a diploma in therapeutic 
education for chronic patients.7 All healthcare 
professionals can attend this 3-year course.  
Research in medication adherence 
A total of 16 studies met the inclusion criterion 
(Tables 2 and 3). The first publication was in 1998. 
Fourteen studies took place at one site; one was 
two-centered8 and the last one was multi-centered.9 
All studies have been published in peer-reviewed 
journals: pharmacology journals, specific medical 
journals, or technology in health-care journals. 
Medication adherence was the primary outcome of 
all studies; 10 studies also measured clinical 
outcomes. Nine studies evaluated the prevalence of 
medication nonadherence as the primary 
outcome.10-18 Three studies evaluated the feasibility 
of new technologies for measuring adherence 
(electronic pill containers, for example the 
Medication Event Monitoring System, MEMSTM the 
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Intelligent Drug Administration System, IDAS IITM 
the MEMSTM monitor connected to a personal 
modem HomeLinkTM.19-21 Eight studies correlated 
nonadherence rate to clinical 
outcomes9,11,12,15,16,18,22,23 and, among them, five 
applied linear regression or multivariate analysis 
methods.9,15,16,18,22 One study evaluated predictors 
of nonadherence.10 Three studies evaluated 
medication adherence enhancing programs.8,9,23 
 
Table 1 Medication adherence courses in Swiss pharmacy schools. 
University Degree (years) Course Content Assessment 
Basel 
 
Master 
(4) 
2-hour course on medication 
adherence 
Theoretical basis, i.e. definition, measurement, 
intervention in the field of adherence in ambulatory 
care. 
Oral exam 
Master 
(5) 
4-hour workshop on medication 
adherence 
Workshop on adherence with asthma treatment, 
patient education and monitoring. 
Oral exam 
 
4-hour workshop on life style 
adherence 
Workshop on smoking cessation, stages of change, 
motivational interview. 
Geneva 
 
Master 
(5) 
4-hour course on medication 
adherence 
Definition of medication adherence and persistence, 
prevalence, risks linked to nonadherence, 
psychological theoretical frameworks, methods for 
evaluating/measuring adherence, program and 
techniques for promoting and supporting adherence, 
case studies. 
Oral exam 
1-hour on empathy Definition and theory, translation into practice, case 
studies 
Oral exam 
2-hour course on patient 
empowerment 
Definition, associated concepts (coping, disease 
management), translation into practice, case studies. 
2-hour therapeutic education Definition and theory, translation into practice, case 
studies 
2-hour motivational interviewing Introduction to motivational interviewing, i.e. its 
specific concepts (resistance, self-efficacy, 
ambivalence) and clinical skills (empathy, reflective 
listening, summaries, etc.); case studies. 
2-hour workshop on interviewing 
techniques  
Discussion of case studies, which students 
encountered during training; role-play. 
Zurich Master 
(5) 
No specific course Medication adherence is taught during other courses, 
especially courses devoted to chronic patient 
treatment, all year through. 
- 
 
Chronic patients were the subjects in 9 studies: 
hypertension9,11,12,20,22 (5), lipid-lowering therapy16 
(1), tuberculosis13 (1), HIV8 (1), and epilepsy23 (1). 
In thirteen studies, patients were included in the 
outpatient medical clinics of three University 
hospitals in Switzerland (Lausanne, Basel and 
Geneva). Only one study took place in the 
community (community pharmacists and GPs)9 and 
two included hospitalized patients.10,19  
Four studies were randomized.9,17,20,23 All studies 
except one10 used electronic monitoring to measure 
medication adherence. Other methods included: pill 
counts, urine testing, self-reported questionnaire, 
and structured interviews with patients. A composite 
score between electronic monitoring, pill count and 
validated pocket-doses was also defined.8,22  
Authors of all sixteen studies were pharmacists and 
physicians. Nurses also participated in one study.8 
For the most part, physicians recruited study 
subjects according to clinical inclusion criteria and 
referred them to pharmacists for the study. This 
suggests that medication adherence is an issue of 
interest to various health-care professionals as they 
share the responsibility with their patients for 
successful adherence. Most of all, it illustrates that 
health-care professionals can collaborate with each 
other as an interdisciplinary team for promoting 
medication adherence and seamless care. 
However, we have to explore whether this kind of 
model can be transferred to community pharmacies 
and primary care practices. An on-going study in 
Switzerland is currently addressing this question.  
Among the eight studies, which correlated 
medication adherence to clinical outcomes, five 
showed a significant association between 
medication adherence and clinical outcomes: better 
medication adherence correlated with improved 
outcomes.12,15,16,18,22 In most studies, medication 
adherence was high, probably because subjects 
knew they were being monitored (Hawthorne 
effect). However, subjects had difficulties adhering 
to complex recommendations (e.g. food restriction, 
refrigerator storage).17 In most studies, attrition rate 
was low and most patients were satisfied with the 
protocol. Three studies evaluated adherence-
enhancing programs in hypertension, HIV and 
epilepsy; these early results are promising. 
Adherence seems to drop faster in control vs. 
intervention groups8 and clinical outcomes appear 
to be superior in intervention vs. control group.9 
Larger, randomized trials are needed to confirm 
these preliminary results. 
The latest intervention8 combined medication 
adherence electronic feedback – measured with 
MEMSTM caps - with motivational interviewing (MI), 
an approach developed by Miller and Rollnick24 to 
promote behavioral change.25 Motivational 
interviewing is tailored to patient’s needs and 
readiness to change behavior.26 The pharmacist 
created an individualized, nonjudgmental and 
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supportive environment allowing each patient to 
become an active partner. The intervention relied on 
Fisher’s information-motivation-behavioral skills 
theoretical framework (IMB), which states that 
adherence-related information, motivation, and 
behavioral skills are fundamental determinants of 
adherence to medication.27,28 The intervention was 
also inspired by social cognitive theory.29,30 During 
the interview, the pharmacist addressed barriers 
and facilitators (cognitive, emotional, behavioral and 
social issues) encountered by the patient, which 
impacted adherence. At the end of each session, 
the patient brought an adherence report and 
summary of the intervention to the subsequent 
physician visit.  
In Switzerland, other healthcare professionals such 
as physicians31, nurses32, psychologists33, 
statisticians1 and health economists34 are interested 
in medication adherence research. Part of this 
research is interdisciplinary: physicians-
pharmacists12,16, physicians-nurses32, physicians-
psychologists.33 
Practice of adherence services and policy 
Community pharmacists are well placed to play a 
key role in supporting patient medication adherence 
as they are easily accessible, can meet with 
patients regularly and share the responsibility with 
the prescriber and the patient for dispensing 
medications efficiently and safely. The pharmacist 
has to answer the patients’ individual needs in 
terms of information, medication handling, and 
practical integration and social acceptance of 
treatment into daily routines. Ideally, the pharmacist 
should address adherence issues empathically with 
their patients from the first time a medication is 
dispensed and offer patients the opportunity to talk 
on an ongoing basis about issues they face with 
their chronic treatment. This requires establishing 
and maintaining an appropriate, nonjudgmental 
environment.  
Patient medication history: a tool for detecting 
nonadherence 
Most community pharmacies in Switzerland are 
equipped with software, which keeps patient 
medication histories: prescribed and dispensed 
medicines, pharmacist comments on clinical data, 
automatic drug interaction checks, and patient 
dosage cards. This history is a useful indicator of 
patient medication renewal rate (Table 4). However, 
the accuracy of such histories can be low especially 
if the patient does not renew his treatment 
systematically at the same pharmacy. If 
nonadherence is detected through the history, an 
assumption for nonadherence should be validated 
with the patient and the issue should be addressed 
empathically. 
In Switzerland, many pharmacies are equipped with 
a little desk on the side, where pharmacists can 
confidentially interview their patients about 
adherence issues.  
Remunerated cognitive pharmaceutical services 
Six types of cognitive pharmaceutical services are 
reimbursed by healthcare insurers in Switzerland, 
the relative costs of which have been defined using 
a system of rated points. In 2009, the cost of one 
rated point equals 0.72 Euros (including taxes).35 
The overall aim of these cognitive services is to 
specify pharmacist tasks when delivering prescribed 
medication to patients and increase trust of patients, 
other healthcare givers and insurers. Among these 
cognitive pharmaceutical services, two are directly 
related to medication adherence and both need to 
be requested by a physician: 
1. Weekly medication adherence fixed fee for 
preparing pill organizers, including electronic 
monitors for patients with a chronic condition, 
who take at least three different medicines 
concomitantly (20 rated points/week).  
2. Direct observed therapy (DOT) fixed fee 
when a patient takes medication in the 
pharmacy under the pharmacist’s supervision 
(usually 10 rated points/delivery; score differs for 
delivery of methadone).  
A new cognitive pharmaceutical service, called 
polymedication check, will be implemented during 
2009. The pharmacist will be reimbursed for a 20 to 
30-minute interview with chronic patients taking at 
least 4 different and concomitant medications with 
the possibility of dispensing a pill organizer during 
the 3 following months. The aim is to tackle complex 
patients who are at risk of drug-related problems 
and/or nonadherence, hence the 4 prescribed 
medications. The interview and the pill-organizer do 
not need to be requested by the physician for 
reimbursement. This service can be repeated every 
6 months.36 This service represents a major 
improvement as, for the first time, interview time 
with the patient is reimbursed and the service does 
not need to be requested by the physician. 
 
CONCLUSIONS 
Specific medication adherence courses have 
entered the curriculum of two out of the three 
pharmacy schools in Switzerland. Pharmacists in 
Switzerland have also been actively involved in 
medication adherence research since the mid 
nineteen nineties. Research has primarily focused 
on nonadherence prevalence. More recently 
researchers have developed and evaluated 
programs for supporting medication adherence to 
long-term treatment. Most of the programs have 
been developed in specific clinic settings, for 
example the community pharmacy of an outpatient 
medical clinic. Present research focuses on the 
transfer of these programs to other community 
pharmacies in Switzerland. In fact, the main 
limitation of the research is that the effectiveness of 
these programs have not been assessed in large, 
multi-centered randomized clinical trials. Moreover 
whether these programs can be implemented 
successfully in non clinic settings i.e. community 
pharmacy, is still unknown.  
Policies in Switzerland are slowly meeting the 
needs of chronic patients via implementation of 
pharmaceutical cognitive services and 
reimbursement fees. However, much still needs to 
be done to improve interdisciplinary collaboration in 
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order to provide seamless care. The role of the 
community pharmacists must evolve to meet the 
adherence challenges of patients with chronic 
diseases. Patient awareness of this shift in the role 
of the pharmacist will also have to be promoted and 
monitored. 
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Table 2: Swiss research studies evaluating adherence. 
Study characteristics Measuring methods for 
adherence 
Study outcomes Results 
Schneider et al.21 Design: pilot, run-in period, 
longitudinal, one-site. 
Aim: to assess if on-line home monitoring of medication 
adherence is feasible and acceptable to chronic 
patients. 
Duration: 2 months 
Number of subjects at inclusion: 7 
Medication adherence 
electronic monitor 
(MEMS) connected to a 
personal modem 
(HomeLink) installed on 
the subject’s telephone 
line. 
Taking adherencea On-line monitoring was well accepted by subjects. 
Adherence improved in 3 patients (from 76% to 90%, 69% 
to 87%, and 83% to 89%). 
Fallab-Stubi et al.13 Design: longitudinal, one-site. 
Aim: to evaluate the usefulness of an electronic monitor 
for measuring adherence to preventive 
chemoprophylaxis of tuberculosis with isoniazid. 
Duration: 6 months. 
Subjects at inclusion: 30 
Continuous electronic 
monitoring of medication 
adherence (MEMS), pill 
count, urine test for 
isoniazid. 
Taking adherence  Mean adherence measured by electronic monitors was 
91% (+/-18.6%). Pill count and urine test tended to 
overestimate adherence when compared to electronic data. 
Combined intervention of pharmacist and physician 
improved medication adherence significantly but transiently 
in all 4 non-adherent patients. 
Schwed et al.16 Design: open, longitudinal, one-site. 
Aim: to monitor adherence to fluvastatin 40mg using an 
electronic device vs. pill count. 
Duration: 6 months 
Sujects at inclusion: 30 
Continuous electronic 
monitoring of medication 
adherence (MEMS), pill 
count. 
Taking adherence, 
dosing adherencea, 
timing adherencea, total 
and LDL-cholesterol. 
Total cholesterol and LDL-cholesterol decreased 
significantly (18% and 25%, p<.001) during the study.  
Taking adherence was 89% +/-13.5%, dosing adherence 
was 82% +/- 19.5% and timing adherence was 82% +/- 
19.5%. Adherence by pill count was 93% +/- 9.5%. A 
significant correlation between adherence and decrease in 
LDL-cholesterol was observed when adherence was 
assessed electronically. 
Arnet et al.10 Design: transversal. 
Aim: to correlate patients’ statements on their 
adherence before hospitalization with their personal 
knowledge and convictions about their treatment. 
Duration:- 
Subjects at inclusion: 100 
One structured interview 
per patient during 
hospitalization on an 
internal medicine ward. 
Self-reported adherence, 
specific knowledge as for 
example name of 
medications, personal 
perception of prescribed 
medication. 
78% subjects reported good adherence, while 13% 
admitted nonadherence. Knowledge was significantly 
better in adherent patients (p=.048). Personal perception 
did not differ by adherers and nonadherers. Subjects used 
3 main strategies to ensure adherence: visual aids (69%), 
coupling to a ritual (26%), supervision by a third person 
(6%).  
Stubi et al.17 Design: randomized, open, one-site. 
Aim: to assess adherence to oral combined to written 
recommendations vs. oral recommendations to live oral 
Ty21a typhoid vaccine in travelers regarding dosing, 
timing with respect to food intake. 
Duration: 5 days 
Intervention:  55 
Control: 60 
Continuous electronic 
monitoring of medication 
adherence (MEMS), pill 
count, self-administered 
questionnaire. 
Percentage of adherers: 
taking all 3 pills, on 
alternate days, at least 
one hour before a meal. 
No difference in adherence was shown by group. All 
subjects took the 2 capsules but only 53% subjects adhere 
to all recommendations according to the electronic 
monitors and 68% to the questionnaire (p=.05). 
  
Table 2: Swiss research studies evaluating adherence. 
Study characteristics Measuring methods for 
adherence 
Study outcomes Results 
Burnier et al.12 Design: one-arm, observational, 
longitudinal, one-site. 
Aim: to evaluate benefits of electronic monitoring of 
medication adherence in the management of patients 
with resistant hypertension. 
Duration: 4 months 
Number of subjects at inclusion: 41 
Continuous electronic 
monitoring of medication 
adherence (each single 
antihypertensive drug was 
delivered in a MEMS 
monitor). For the first 2 
months, patient’s usual 
treatment was provided in 
MEMS without any 
other intervention; for the 
next 2 months, treatment 
could be adapted if 
necessary. 
Dosing adherence, blood 
pressure. 
Monitoring of adherence alone was associated with an 
improvement in BP (p<.01). BP was normalized in one-
third of patients. Patients with lowest adherence had higher 
diastolic BP (p=.04). 
Bertholet et al.11 Design: retrospective, one-site. 
Aim: to evaluate whether the use of electronic 
monitoring for medication adherence is a useful 
approach to identify compliance problems in 
hypertensive patients. 
Duration: 2 months 
Number of subjects at inclusion: 69 
Continuous electronic 
monitoring of medication 
adherence (one MEMS 
monitor per medication) 
Taking adherence, blood 
pressure. 
Significant decrease in BP (from 159/104 +/-23/12 mmHg 
to 143/92 +/-20/15, p<.001) after inclusion. BP was 
normalized in one third of patients. Mean adherence of 
patients with normalized BP was 90.7% (range, 64-100%), 
and was similar in the non-normalized patients. 
Arnet et al.19 Design: open, longitudinal, one-site. 
Aim: to evaluate accuracy of electronic adherence 
monitoring of an oral vitamin combination. 
Duration: 3 weeks 
Subjects at inclusion: 37 
Continuous electronic 
monitoring of medication 
adherence (MEMS), pill 
count, patient interviews. 
Taking adherence Taking adherence was 102%. Pill boxes were opened 
>once a day by 10 patients on a least one monitored day. 
In 7 patients, the number of openings exceeded the 
number of capsules provided but only 2 patients admitted 
overconsumption.  
Wermeille et al.18 Design: longitudinal, one-site. 
Aim: to evaluate if poor adherence is a predictor of low 
Helicobacter pylori eradication. 
Duration: one week 
Subjects at inclusion: 78 
Continuous electronic 
monitoring of medication 
adherence (MEMS). 
H. pylori eradication rate, 
percentage of subjects 
taking more than 85% of 
their doses. 
H. pylori eradication rate was 65% (95% CI: 54.8-76.0%). 
89% of subjects were adherers. On multivariate analysis, 
H. pylori eradication was inversely associated with poor 
adherence (p=.029). Poor adherence and bacterial 
resistance explained 40% of failures. 
Schneider et al.15 Design: one-arm, longitudinal, one-
site. 
Aim: to characterize use of a nicotine nasal spray 
(NNS) in smoking cessation. 
Duration: 18 months 
Number of subjects at inclusion: 92 
Nasal spray use was 
monitored by a microchip 
fixed on the spray unit 
(microswitch-actuated 
metered-dose inhaler 
chronolog, MDILog). 
Number of abstainers at 
12 and 4 months; pattern 
of use of NNS. 
Success rate was 17.4% at 12 and 9.8% at 24 months.  
Abstainers use NNS more than failures (12 vs. 6 puffs/day, 
p=.05), use it less in the morning compared with failures 
(26.6 vs. 32.8% of total median daily dose, p=.03) but used 
it more in the evening/night (35.3 vs. 26.7% of total median 
daily dose, p=.007).  
  
Table 2: Swiss research studies evaluating adherence. 
Study characteristics Measuring methods for 
adherence 
Study outcomes Results 
Landry et al.14 Design: open, longitudinal, 
observational. 
Aim: to assess adherence to mefloquine malaria 
chemoprophylaxis in adult travelers to sub-Saharan 
Africa. 
Duration: variable  
Number of subjects at inclusion: 81 
Continuous electronic 
monitoring of medication 
adherence (MEMS), 
self-administered 
questionnaire on drug 
intake 
Taking of all the tablets 
at the right day. 
Only 26 travelers (32%) took all the doses at the expected 
date.  19/81 (24%) took them with intervals of +/- 1 day. 
Santschi et al.20 Design:  randomized, cross-over. 
Aim: to evaluate acceptability of IDAS II, a new 
electronic device for monitoring adherence in 
hypertension 
Duration: 2x2 months 
Number of subjects at inclusion: 24 
Intelligent Drug 
Administration System 
(IDAS II electronic 
monitor) vs. MEMS 
monitor as control. 
Patients’ opinion on both 
devices, rates of 
adherence, blood 
pressure. 
Patients found MEMS easier to use than IDAS 
(p<.001) but appreciated IDAS blister packs better than 
MEMS bulk packaging (p<.01). Median taking adherence 
was 99% and comparable with both devices. No difference 
in blood pressure between groups. 
Figueiredo et al.22 Design: retrospective, one site. 
Aim: to describe systolic blood pressure (SBP) and 
model it during an adherence-enhancing intervention 
program in patients resistant to their treatment. 
Duration:  variable  
Subjects: 89 
Continuous electronic 
monitoring of medication 
adherence (MEMS), 
combined to repeated 
interviews with subjects. 
Composite adherence 
score between electronic 
monitoring, pill count and 
validated pocket-doses. 
Quality of executiona, 
blood pressure. 
Quality of execution was high and stable over time. The 
average decrease in SBP from baseline was 15mmHg. 
SBP decreased as quality of execution increases with a 
maximum around 85% adherence. 
aTaking adherence is the percentage of openings of the device divided by the number of prescribed doses. Dosing adherence is the percentage of days with correct dosing. 
Timing adherence is the percentage of openings of the device with a correct timing (+/-25% of prescribed interval). Quality of execution:  data are summarized in a sequence of 
binary data, Zij, indicating whether yes (1) or no (0), at least one of the medicines was taken as prescribed on day j by patient i. 
 
 
Table 3: Swiss research studies evaluating medication adherence enhancing programs. 
Study characteristics Intervention Study outcomes Study results 
Schneider et al.23  Design : randomized, controlled, open, one-site 
Aim: to evaluate the benefit of online telemonitoring of medication 
adherence in epilepsy. 
Duration:  8 months 
Intervention:  12 
Control: 14 
Electronic monitors of medication adherence 
(MEMS) connected to a personal modem 
(HomeLink) installed on the subject’s 
telephone line vs. electronic monitors only in 
controlled subjects. Pharmacist called patient 
at home in case of drug omission. 
Taking, dosing and 
timing adherence, 
seizure frequency. 
Dosing adherence was high and similar in both 
groups. There was a trend towards less epileptic 
events in the intervention vs. the control group 
(p=.07). 
Santschi et al.9 Design: cluster randomized, controlled, and multi-
sites. 
Aim: to examine whether monitoring medication adherence with an 
electronic system improves BP control in uncontrolled patients 
followed by GPs. 
Duration : 12 months 
Intervention : 34 
Control : 34 
Electronic monitoring of medication adherence 
(MEMS), plus non-structured repeated 
interviews at the pharmacy in the intervention 
group vs. electronic monitors only in control 
group.  
Normalized BP 
(<140/90 mmHg) 
Likelihood of reaching target BP was higher in 
intervention group compared to control group 
(p<.05). At 4 months, 38% patients in intervention 
group reached target BP vs. 12% patients in control. 
(p<.05), and 21% vs. 9% at 12 months (p=ns). 
Multivariate analysis showed that being allocated to 
intervention group was associated with a greater 
odds of reaching target BP at 4 (p<.01) and 12 
months (p=.051). 
Krummenacher et al.8 Design: pilot, quasi-experimental, two-sites. 
Aim:  to evaluate the feasibility of an interdisciplinary and 
multifactorial adherence program in HIV patients starting a first or a 
second antiretroviral therapy line. 
Duration: 6 months 
Intervention: 21 
Control: 11 
Continuous electronic monitoring of medication 
adherence (MEMS), combined to repeated 
motivational interviewing in intervention vs. 
blinded medication adherence electronic 
monitoring in control group. 
Composite adherence score between 
electronic monitoring, pill count and validated 
pocket-doses. 
Quality of execution 
and persistence. 
The study was feasible in one site but not in the 
other one. Quality of execution was high in both 
groups (97% vs. 95%) but decreased statistically 
more over time in the control versus the intervention 
group (p<.0001). 
 
Table 4: Example of a patient’s medication history showing the timing of dispensation and the number of tablets dispensed per month. 
Mr O.V. 81 years old                                           2008 
  Dosage Regimen  JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC 
Acetylsalicylic acid  300mg 1-0-0-0    90  90   90   90  
Enalapril  20mg 1-0-0-0    100 100    100   100  
Indapamide SR  1.5mg 1-0-0-0  90   90   90   90   
Amlodipine  5mg 1-0-0   30 100   100   100   100 
Nateglinide  60mg 1-1-1    168 84 84  168 84  168 84  
Atorvastatin  10mg 1-0-0      30 30 100   100   
Calcium/cholecalciferol  500mg/400UI 2-0-0  120   120 120  120   120 120  
Acetaminophen  1000mg 1 to 2 tab/24h  80  20 40 60   80  20 40  
Acetaminophen  500mg         32      
 
